

1449/IPS

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **2**

### Complete If Known

Application Number	10/058,636
Filing Date	January 29, 2002
First Named Inventor	Gilbert, Michel
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	019957-013211US

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AU							
	AV							
	AW							
	AX							
	AY							

Examiner  
Signature

Date  
Considered

12/23/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1345085 v1

<b>Notice of References Cited</b>	Application/Control No. <b>10/058,636</b>	Applicant(s)/Patent Under Reexam <b>Gilbert et al</b>	
	Examiner <b>Portner</b>	Art Unit <b>1645</b>	Page 1 of 1

### U.S. PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY <sup>1</sup>	Name	Classification <sup>2</sup>	
A	6,096,529	8/2000	Gilbert et al	435	252.3
B	6,399,336	6/2002	Paulson et al	435	97
C	5,494,790	2/1996	Sasaki et al	435	6
D					
E					
F					
G					
H					
I					
J					
K					
L					
M					

### FOREIGN PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY <sup>1</sup>	Country	Name	Classification <sup>2</sup>	
N						
O						
P						
Q						
R						
S						
T						

### NON-PATENT DOCUMENTS

	Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
	Gilbert, Michel et al, The Journal of Biological Chemistry, Vol. 271(8), November 8, 1996, pages 28271-28276.
V	Moran, AP et al, Journal of endotoxin research, Vol. 3(6), December 1996, pages 521-531.
W	
X	

\* A copy of this reference is not being furnished with this Office action. See MPEP § 707.05(a).

<sup>1</sup> Dates in MM-YYYY format are publication dates.

<sup>2</sup> Classifications may be U.S. or foreign.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/058,636
		Filing Date	January 29, 2002
		First Named Inventor	Gilbert, Michel
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	019957-013211US
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
(B)	46	Bowie et al. <i>Science</i> 257:1306-1310 (1990).	
↓	47	Burgess et al. <i>J. Cell Bio.</i> 111:2129-2138 (1990)	
↓	48	Lazar et al. <i>Mol. Cell. Biol.</i> 8:1247-1252 (1988).	
↓	49	Yamashiro et al. <i>Glycoconjugate J.</i> 12:894-900 (1995).	
↓	50	Yuki et al. <i>J. Neurological Sciences</i> 130:112-116 (1995).	
	51		
	52		
	53		
	54		
	55		
	56		

Examiner Signature		Date Considered	12/23/05
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1345085 v1

COPY OF PAPERS  
ORIGINALLY FILED

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number 10/058,636  
Filing Date January 29, 2002  
First Named Inventor Gilbert, Michel  
Group Art Unit 1645  
Examiner Name Unassigned  
Attorney Docket Number 019957-013211US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					

RECEIVED  
JUL 05 2002  
TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AU							
	AV							
	AW							
	AX							
	AY							

Examiner Signature

Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 602. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1345085 v1

COPY OF PAPERS  
ORIGINALLY FILED

Please type a plus sign (+) inside this box.


PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		JUL 01 2002	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/058,636
		Filing Date	January 29, 2002
		First Named Inventor	Gilbert, Michel
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet	2	of	2
		Attorney Docket Number	019957-013211US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	46	Bowie et al. Science 257:1306-1310 (1990).	
	47	Burgess et al. J. Cell Bio. 111:2129-2138 (1990)	
	48	Lazar et al. Mol. Cell. Biol. 8:1247-1252 (1988).	
	49	Yamashiro et al. Glycoconjugate J. 12:894-900 (1995).	
	50	Yuki et al. J. Neurological Sciences 130:112-116 (1995).	
	51		
	52		
	53		
	54		
	55		
	56		

Duplicate

Examiner Signature		Date Considered	12/23/01 5/14/02
--------------------	---	-----------------	---------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1345085 v1

Please type a plus sign (+) inside this box





PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Unknown
				Filing Date	Herewith
				First Named Inventor	Gilbert, Michel, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	5	Attorney Docket Number	019957-013211US

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	US 5,352,670		Venot, et al.	10-04-1994	
	AB	US 5,374,541		Wong, et al.	12-20-1994	
	AC	US 5,545,553		Gotschlich	08-13-1996	
	AD	US 5,998,138		Stonnet, et al.	12-1999	
	AE	US 5,691,138		Guesdon, et al.	11-1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	BA	EP	173149A		Hoechst AG			
	BB	PCT	WO 96/32491			10-17-1996		
	BC	PCT	WO 97/47749			12-18-1997		
	BD	PCT	WO 98/31826			07-1998		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1310387 v1

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Unknown
		Filing Date	Herewith
		First Named Inventor	Gilbert, Michel, et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	019957-013211US
Sheet	2	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Aoki et al., "Analysis of the substrate binding sites of human galactosyltransferase by protein engineering," <i>EMBO J.</i> 9:3171-3178 (1990).	
	2	Aspinall et al., "Lipopolysaccharides of <i>Campylobacter jejuni</i> Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barre Syndrome," <i>Biochemistry</i> 33: 241-249 (1994).	
	3	Aspinall, et al. "Lipopolysaccharides of <i>Campylobacter jejuni</i> Serotype O:19: Structures of O Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barre Syndrome," <i>Biochemistry</i> 33: 250-255 (1994).	
	4	Bradbury, et al. <i>J. of Clinical Microbiol.</i> , (September 1985) Vol. 22(3), pages 339-346, (abstract only)	
	5	Chang, et al. <i>Glycobiology</i> , (May 1995) Vol. 5(3), pages 319-325.	
	6	Frosch et al., "Evidence for a common molecular origin of the capsule gene loci in Gram-negative bacteria expressing group II capsular polysaccharides," <i>Mol. Microbiol.</i> 5: 1251-1263 (1991).	
	7	Gilbert et al., "Cloning of the Lipooligosaccharide a-2-3-Sialyltransferase from the Bacterial Pathogens <i>Neisseria meningitidis</i> and <i>Neisseria gonorrhoeae</i> ," <i>J. Biol. Chem.</i> , 271:28271-28276 (1996).	
	8	Gilbert et al., "Characterization of a recombinant <i>Neisseria meningitidis</i> a-2,3-sialyltransferase and its acceptor specificity," <i>Eur. J. Biochem.</i> 249: 187-194 (1997)	
	9	Gibert, et al. "The Synthesis of Sialylated Oligosaccharides Using a CMP-Neu5Ac Synthetase/sialyltransferase Fusion" <i>Nature Biotechnology</i> (August 1998) Vol. 16, pages 769-772.	
	10	Gillam and Smith, "Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotide Primers: I. Optimum Conditions and Minimum Oligodeoxyribo-Nucleotide Length," <i>Gene</i> 8:81-97 (1979).	
	11	Guo, et al. <i>Applied Biochemistry and Biotechnology</i> , Oct-Nov 1997, Vol. 68 (1-2), pages 1-20.	
	12	Imai, et al. <i>Cytobios.</i> (1994) Vol. 78(313), pages 115-122 (abstract only)	

Examiner Signature		Date Considered	12/23/08
--------------------	--	-----------------	----------

\* EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1310387 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Unknown		
		Filing Date	Herewith		
		First Named Inventor	Gilbert, Michel, <i>et al.</i>		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	3	of	5	Attorney Docket Number	019957-013211US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓	13	Ito et al., <i>Pure Appl. Chem.</i> , "Synthesis of Bioactive sialosides," 65:753 (1993).	
	14	Jamieson, <i>et al. Comparative Biochemistry and Physiology</i> , (1993) Vol. 105(1), pages 29-33.	
	15	Kajihara et al., "A Novel a-2,6-Sialyltransferase: Transfer of Sialic Acid to Fucosyl and Sialyl Trisaccharides," <i>J. Org. Chem.</i> 61: 8632-8635	
	16	Kleene et al., "Expression of Soluble Active Human B1, 4 Galactosyltransferase in <i>Saccharomyces Cerevisiae</i> ," <i>Biochem. Biophys. Res. Commun.</i> 201:160-167 (1994).	
	17	Klohs, <i>et al. Cancer Res.</i> , (1979) Vol. 39(4), pages 1231-1238.	
	18	Korolik, <i>et al. Microbiology</i> , (November 1997) Vol. 143(pt11), pages 3481-3489.	
	19	Kuroki et al., " <i>Campylobacter jejuni</i> Strains from Patients with Guillain-Barre Syndrome Belong Mostly to Penner Serogroup 19 and Contain B-N-Acetylglucosamine Residues," <i>Ann Neurol</i> 33:243-247. (1993).	
	20	Mandrell, <i>et al. Immunobiology</i> , (1993) Vol. 187(3-5), pages 382-402.	
	21	Maskell, <i>et al. Mol. Microbiol.</i> , (1991) Vol. 5(5), pages 1013-1022, (abstract only)	
	22	Moran et al., "Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease," <i>MS Immunol. Med. Microbiol.</i> 16:105-115 (1996).	
	23	Moran et al., "Molecular mimicry of host structures by lipopolysaccharides of <i>Campylobacter</i> and <i>Helicobacter</i> spp: implications in pathogenesis," <i>J. Endotoxin Res.</i> 3:521-531.	
	24	Nishiu et al., "Characterization of Rat N-Acetylglucosaminyltransferase I Expressed in <i>Escherichia coli</i> ," <i>Biosci. Biotech. Biochem.</i> 59 (9):1750-1752 (1995).	
✓	25	Parsons, <i>et al. Microbial Pathogenesis</i> , ( 1993) Vol. 14(4), pages 329-335.	

Examiner Signature		Date Considered	12/23/08
--------------------	--	-----------------	----------

\* EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1310387 v1





Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>Unknown</td> </tr> <tr> <td>Filing Date</td> <td>Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Gilbert, Michel, et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>019957-013211US</td> </tr> </table>		Complete if Known		Application Number	Unknown	Filing Date	Herewith	First Named Inventor	Gilbert, Michel, et al.	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	019957-013211US
Complete if Known																	
Application Number	Unknown																
Filing Date	Herewith																
First Named Inventor	Gilbert, Michel, et al.																
Group Art Unit	Unassigned																
Examiner Name	Unassigned																
Attorney Docket Number	019957-013211US																
Sheet	4	of	5														

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	26	Preston et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," <i>Crit. Rev. Microbiol.</i> 22:139-180.	
	27	Rest, et al. <i>Microbial Pathogenesis</i> , (1995) Vol. 19(6), pages 379-390.	
	28	Reuter et al., "Sialic Acids Structure – Analysis – Metabolism – Occurrence – Recognition," <i>Biol. Chem. Hoppe-Seyler</i> 377:325-342	
	29	Roberts et al., "Generation of an antibody with enhanced <i>Nature</i> 328:731-734 (1987).	
	30	Ropper, "The Guillain-Barre Syndrome," <i>N. Engl. J. Med.</i> 326: 1130-1136.	
	31	Salloway, et al. <i>Infection Immunity</i> , (August 1996) Vol. 64(8), pages 2945-2949.	
	32	Smith, et al. <i>Microbial Pathogenesis</i> , (1995) Vol. 19(6), pages 365-377.	
	33	Steenbergen, et al. <i>Journal of Biochemistry</i> , (February 1998) Vol. 174(4), pages 1099-1108.	
	34	Skirrow, <i>Brit. Med. J.</i> "Campylobacter enteritis: a 'new' disease," 2:9-11 (1977).	
	35	Taylor, et al. <i>Antimicrobial Agents &amp; Chemotherapy</i> (December 1983), Vol. 24(6), pp. 930-935, (abstract only).	
	36	Taylor, et al. <i>Antimicrobial Agents and Chemotherapy</i> , (May 1981) Vol. 19(5), pages 831-835 (abstract only)	
	37	Varki, "Biological Roles of Oligosaccharides: all of the theories are correct," <i>Glycobiology</i> 3:97-130.	
	38	Vogel, et al. <i>Medical Microbiology and Immunology</i> , (October 1997) Vol. 186(2-3), pages 159-166.	

Examiner Signature	Date Considered <span style="font-size: 1.5em;">12/23/08</span>
--------------------	---

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1310387 v1

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	Unknown
		Filing Date	Herewith
		First Named Inventor	Gilbert, Michel, et al.
		Group Art Unit	Unassigned 1648
		Examiner Name	Unassigned
Sheet 5 of 5	Attorney Docket Number	019957-013211US	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓	39	Weiser, et al. <i>Critical Reviews in Clinical Laboratory Sciences</i> , (June 1981) Vol. 14(3), pages 189-239.	
✓	40	Weisgerber et al., "Complete nucleotide and deduced protein sequence of CMP-neuAc: poly-a-2,8 sialosyl sialyltransferase of <i>Escherichia coli</i> K1," <i>Glycobiol.</i> 1:357-365 (1991).	
✓	41	Williams et al., "Large-scale expression of recombinant sialyltransferases and comparison of their kinetic properties with native enzymes," <i>Glycoconjugate J.</i> 12: 755-761.	
✓	42	Wakarchuk et al., "Mutational and crystallographic analyses of the active site residues of the <i>Bacillus circulans</i> xylanase," <i>Protein Sci.</i> 3:467-475	
✓	43	Yamamoto et al., "Purification and Characterization of a Marine Bacterial B-Galactoside a2,6-Sialyltransferase from <i>Photobacterium damsela</i> JT0160," <i>J. Biochem.</i> 120:104-110 (1996).	
✓	44	Yamamoto, et al. <i>J. of Biochemistry</i> , (January 1998) Vol. 123(1), pages 94-100.	
✓	45	Yamashiro, et al. <i>Glycoconjugate Journal</i> , (December 1995) Vol. 12(6), pages 894-900.	

Examiner Signature		Date Considered	12/23/02
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1310387 v1